Real-World Evidence over the Medicine’s Lifecycle to Inform HTA/Payer Decisions

November 23, 2023
09:00-14:00 CET
In-person

BIP Meeting Center (Room ‘Salles des Guichets’), Rue Royale 2-4, 1000 Bruxelles

Programme

09:00

Registration opens

Hans-Georg Eichler

Consulting physician, Association of Austrian Social Insurance Institutions

Karen Facey

Senior Adviser HTA, FIPRA RWE4Decisions Facilitator

09:35 – 09:45

Data policies and patient access – EU Spanish Presidency priorities

Enrique Terol García

Coordinating Advisor on Health, Permanent Representation of Spain to the European Union

09:45 – 10:50

The Policy Context for Real-World Evidence

Marco Marsella

Director of Digital, EU4Health and Health Systems Modernisation, DG SANTE, European Commission

Patrice Verpillat

Head of Real-World Evidence Workstream, European Medicines Agency

Dimitrios Athanasiou

Board Member, World Duchenne Organisation

Alexander Natz

Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

10:50 – 11:00

Learnings about Real-World Evidence Generation and Evaluation

Karen Facey

Senior Adviser HTA, FIPRA International RWE4Decisions Facilitator

11:00 – 11:25

Break

11:25 – 12:20

The Potential for Collecting Real-World Data in Early Access to Inform HTA/Payer Decisions

Entela Xoxi

Senior Researcher, Università Cattolica del Sacro Cuore Roma

Camille Thomassin

Head of the Real-World Evidence Coordination Unit, Haute Autorité de Santé (HAS)

Jo de Cock

Former CEO, National Institute of Health and Disability Insurance, Belgium (INAMI-RIZIV)

Andre Vidal Pinheiro

Vice-President, Head of Patient Value & Access EUCAN, Global Pricing & Access, Takeda

12:20 – 12:55

Closing Session: Building Better RWE for Decisions – What’s Next?

Pedro Facon

Deputy CEO, National Institute of Health and Disability Insurance, Belgium (INAMI-RIZIV)

Niklas Hedberg

Chief Pharmacist, Swedish Dental and Pharmaceuticals Benefits Agency (TLV)

Matti Aapro MD

Oncologist, Genolier Cancer Center

Simone Boselli

Public Affairs Director, EURORDIS-Rare Diseases Europe

Eline Van Overbeeke

Director, Global Access Strategy, DMD Gene Therapy, Pfizer

12:55 – 13:00

Looking ahead to 2024 – the RWE4Decisions agenda

Hans-Georg Eichler

Consulting Physician, Association of Austrian Social Insurance Institutions

13:00 – 14:00

Lunch

Other past events

Public Webinar: From Policy to Practice: EHDS Implementation to Support Better Real-World Evidence for HTA/Payers

April 9, 2025
15:00-16:30 CEST
Online

RWE4Decisions Symposium: Developing Real-World Evidence to Deliver Innovation in HTA

November 14, 2024
09:00-13:00 CET
Hybrid

Public Webinar: HTA/Payer Collaboration in the Nordics: The Role of Real-World Evidence

October 23, 2024
15:00-16:00 CEST
Online